With over 700 million people suffering from obesity worldwide, BariaTek Medical, founded by Truffle Capital, aims to provide a reliable and safe alternative to traditional bariatric surgery through minimally invasive endoscopic devices. The company's goal is to mimic the efficacy of surgery while surpassing it in terms of safety and ease of use. As treating overweight-related conditions is projected to cost G-20 nations over $1.3 trillion per year by this decade, BariaTek Medical's approach could have a significant impact on both patient outcomes and healthcare costs.